CMS released a fact sheet on a proposed rule that would reduce generic drug copayments from $1 to $0 for certain full-benefit dual eligibles in Part D and add pharmacy benefit manager accountability provisions. The proposal is directly relevant to beneficiary affordability and plan oversight, with a narrower focus than previous broad drug-cost or Medicare reform posts. If finalized, the change would eliminate a small but recurring out-of-pocket charge for some low-income enrollees.
